mRNA Display and Macrocycle Patents: Leaders & White Space 2026
mRNA Display and Macrocycle Library Patents: Who Holds the Ground
Filing is concentrated but not locked up. the ranked leader holds 270 records yet the top 5 combined account for only 18.9% of the 6,089 records in scope. Annual filings climbed to a peak of 458 in 2021, then fell to 244 by 2024 — a 47% decline over that three-year span. 2025 and 2026 figures are not yet comparable: publication typically lags filing by around 18 months, so the most recent years understate true filing activity and should not be read as a continued slide.
- 1NGM BIOPHARMACEUTICALS INC4.4%
- 2JANSSEN BIOTECH INC4.3%
- 3ABBVIE INC3.5%
- 4GENENTECH INC3.4%
- 5XOMA US LLC3.3%
See the full mrna display and macrocycle libraries analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
How concentrated is mRNA display and macrocycle library patent ownership?
Ownership is concentrated at the top but not locked up by a single player. The leading assignee holds 270 of the 6,089 records in scope, and the top 5 combined account for 18.9% of all records. The top 10 combined reach 29.9%, which means more than two-thirds of the corpus sits with assignees outside the top 10 — a long tail typical of a platform technology still being explored by many groups rather than owned by a handful.
Is patent filing activity in this space growing or slowing?
Filing peaked in 2021 at 458 records and had fallen to 244 by 2024, a 47% decline over that three-year span. However, patent publication typically lags filing by around 18 months, so figures for 2025 and 2026 in this dataset are still incomplete and should not be treated as confirmation the field is continuing to shrink. The more defensible reading is that activity has pulled back from an unusually active 2021 rather than that the underlying technology has stalled.
Which patent classes matter most for mRNA display and macrocycle libraries?
C07K (peptides and proteins) appears in 75.7% of the 6,089 records and A61K (medicinal preparations) in 49.4%, reflecting that most filings ultimately claim a molecule or its therapeutic use. C12N (microorganisms and genetic engineering) and A61P (therapeutic activity) follow at 31.9% and 26.1%. C40B, the class specific to combinatorial chemistry libraries, covers only 12.9% of records, which is notably thin given how central library construction is to the underlying platform.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on mRNA Display and Macrocycle Libraries covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.